Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines’ Groundbreaking Pancreatic Cancer Drug
Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.
·
The Motley Fool
Why Qualcomm Stock Fell 9% Despite Beating Earnings Estimates
Investors are worried the future may not be nearly as bright as management suggests, or arrive there as quickly as implied.
·
The Motley Fool
Tesla’s FSD (Supervised) Attach Rate Hit 75% on New Vehicles. Here’s Why That Single Number Could Matter More Than Robotaxi for the Stock in 2027.
Tesla's growing subscriber base deserves more attention.
·
The Motley Fool
How These 4 Transportation Stocks Move the Economy
Railroads and delivery giants did the heavy lifting for the economy this year. Their latest earnings show how.
·
The Motley Fool
Obamacare Subsidies Lapsed. Here’s Why Health Insurer Stocks Are Watching the New Congress.
More government subsidies for households to pay for health insurance may be introduced, which could help grow Obamacare premiums.
·
The Motley Fool
Social Security Is Teetering, and 3 of President Donald Trump’s Policies Are Helping to Push It Over the Edge
Social Security’s already precarious financial outlook has worsened under President Trump.
·
The Motley Fool
Is a Market Crash Coming? Warren Buffett’s Warning Is Ringing Loud and Clear.
Buffett has successfully invested through all kinds of markets over decades and is worth listening to.
·
The Motley Fool
